Upper limb lymphedema is one of the most underestimated and debilitating complications of breast cancer treatment. Hitherto, lymphedema treatment options have mainly been based on the lifelong application of a combination of conservative techniques, such as compression garments/bandages and manual lymph drainage.\(^1\)\(^-\)\(^3\) Conservative therapy is initially aimed at alleviating symptoms without curative intent; with such treatment, some patients may achieve sufficient limb volume reduction and symptom relief. In cases of inadequate disease management, lymphedema may
progress: arm-swelling transforming from a predominantly fluid encompassing entity to fibrosis and fat.4,5 Lymphedema in its late chronic phase is irreversible and accompanied by more symptoms and physical impairments, consequently compromising the quality of survivorship.6–10 An alternative treatment option could be beneficial for patients that are not responsive to standard conservative therapy. Lymphatic microsurgery could be such a treatment option, if treatment would be applied before lymphedema reaches its chronic, irreversible phase.

Derivative (Super) Microlymphatic Surgery

Microlymphatic repair for lymphedematous limbs emerged with the development of reconstructive microsurgery in the late 1960s. The very first experimental studies reported were in obstructive canine models. In these studies, communications were created between the lymphatic and venous systems to divert static lymph fluid away from the obstruction site in a technique called lymphatic venous anastomoses.11 The canine studies reported low and inconsistent patency rates as the result of this intervention, triggering the further development of the derivative microlymphatic technique. Refinements were made to reduce the chances of venous backflow and, consequently, bypass stenosis. However, limitations in the available microsurgical technology hampered the long-term establishment of viable anastomoses, as the pressure gradient between the lymphatic and venous systems were still too high. Until the beginning of this millennium there was little progression in lymphatic surgical techniques. In the contemporary clinical field of microvascular surgery, anastomoses with vessels as small as 0.3 mm in diameter are possible; this is also known as “super microsurgery.” Because of these technical refinements, it is now possible to create multiple bypasses between lymphatic (ranging from 0.3 to 0.5 mm) and venular vessels (0.5 mm) found in the subdermal plane of a lymphedematous limb. Anastomosing smaller vessels of the two vascular systems is hypothesized to ensure better bypass patency due to the minor intravascular pressure differences.12 Over the years evidence has been reported of lymphatic repair being effective in patients with secondary lymphedema of both the upper and lower extremities using lymphatic venular anastomoses.13–15

Tissue Transfer

Another technique to improve lymphatic drainage is the vascularized lymph node transfer with or without simultaneous free flap reconstruction.16 Experimental studies on lymph node transplantation in small animal studies have reported promising results of lymphatic function restoration, and with that, the facilitation of lymphedema resolution.17,18 Moreover, an alternative approach is achieved through the interposition of autologous tissue (i.e., lymph vessel), in which an attempt is made to restore flow within a damaged lymphatic system by bypassing the site of blockage. The transplanted lymph vessel(s) can function as a bridge connecting the afferent and efferent lymphatic vessels from the obstruction site.19

The recent movement toward the incorporation of evidence-based medicine into plastic surgery20 has stressed the importance of good quality research as the core of the clinical decision-making process. The primary aim of this systematic review is to summarize the recent literature for evidence of the effectiveness of lymphatic microsurgery for the treatment of breast cancer–related lymphedema (BCRL). Specifically, the effect of surgery on upper-limb volume/circumference reduction, symptom relief, lymph flow improvement, and the discontinuation of compression therapy postoperatively will be evaluated.

Methods

Literature Search

An electronic search was conducted in MEDLINE and PubMed for literature published from January 2000 until January 2012. Three independent investigators (TLP, NH, CI) performed the search. The following search terms were used: lymphoedema, lymphedema, microsurgery, surgical treatment, breast cancer, lymph node transfer, lymphovenous anastomoses, lymphatico-venular anastomoses, and lymph vessel transplantation. The search was limited to English, Dutch, German, and French literature, and we also hand-searched reference lists of the relevant articles found. Abstracts were scanned for relevance.

Only the studies providing data on patients with secondary lymphedema after breast cancer treatment and those examining the effectiveness of microsurgical intervention were eligible for inclusion. Data from studies on primary lymphedema, lower extremity lymphedema, and mixed groups of lower and upper extremity lymphedema were excluded. All articles were evaluated for duplicate reporting on the same patient population and if so removed.

Data Extraction

The following data were extracted if available: surgical intervention type (lymph node transplantation, lymph vessel transplantation, or derivative lymphatic surgery), size of the patient population, mean follow-up time, BCRL classification or stage, mean duration of BCRL before surgery, arm volume or circumference reduction, lymph flow improvement as quantified by lymphoscintigraphy, symptom relief (self-perceived pain, heaviness, and erysipelas), discontinuation of postoperative conservative therapy (compression garments/bandages or manual lymphatic drainage) and complications (donor or recipient site morbidity).

Quality Assessment

A detailed methodological quality assessment was conducted independently by three investigators (TLP, CI, NH). The studies were assessed using an 8-question checklist from The American Society of Plastic Surgeons (ASPS) for therapeutic studies.21 Each affirmative answer was a point. Thus, a total score of 8 was the maximum to be assigned per study. The quality scores were compared and disagreements resolved by consensus.
Data Analysis

The median and range of the methodological quality rating of all the studies combined, as well as the studies per surgical technique, are provided. We compared the median quality ratings using the Mann-Whitney U test. A p value <0.05 was considered significant. Data analysis was conducted using SPSS for Mac 17.0 (SPSS Inc. Chicago, IL, USA). As for pooling study results, this was not possible due to substantial clinical heterogeneity between the studies with respect to the outcomes of interest and the characteristics of the patient populations. As an alternative, we have therefore chosen to present the characteristics and primary outcomes of each study separately in a schematic overview, according to the microsurgical technique that was used.

Results

There were no randomized clinical trials or comparative studies available, thus we were limited to the inclusion of case series. A total of 19 case series were identified. Nine were excluded, as they described either lymphedema of only the lower extremity, a mix of lower and upper extremity lymphedema, a mix of primary and secondary upper extremity lymphedema. The remaining 10 studies were included for assessment (Table 1). In these studies, three types of microlymphatic surgery were described: composite tissue transfer, lymphatic vessel transfer, and derivative surgery. The number of patients per case series was small, ranging from 6 to 24 women. However, one study reported evidence on 127 women. Follow-up time varied amongst the studies, ranging from 5 to 72 months in articles evaluating derivative lymphatic surgery and 6 to 132 months in those evaluating (composite) tissue transfer. Different measures were used to assess treatment outcome. These included reduction of limb volume, circumference, or symptomatology and improvement of lymphatic function quantified by lymphoscintigraphy.

Quality Assessment

The median methodological quality rating of the 10 studies was 4.5 (range 2 to 5) (Table 1). The studies on (composite) tissue transfer had a higher median quality score compared with that of derivative techniques, respectively 5 (range 2 to 5) versus 4 (range 3 to 5). However, this difference was not statistically significant (p = 0.567).

(Composite) Tissue Transfer

A total of four retrospective case series (n = 52) on composite tissue transfer for the treatment of BCRL were identified (Table 2). Three (n = 39) described a similar operative technique: lymph nodes harvested at the inguinal site with the vascular structures and fat surrounding the superficial circumflex iliac vessels set in the axilla of the affected limb using the thoracodorsal vessels as recipient vessels. Of these three, Saaristo et al modified the technique by combining it with a deep inferior epigastric perforator/muscle-sparing transverse rectus abdominis muscle (DIEP/mSTAM)

<table>
<thead>
<tr>
<th>Study</th>
<th>Cases selected appropriately</th>
<th>Consecutive cases</th>
<th>FU time sufficient to detect outcome</th>
<th>Procedures performed by 1 surgeon</th>
<th>Outcomes measured with validated, defined criteria</th>
<th>Free of conflicts of interest</th>
<th>Total score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lin et al</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>5</td>
</tr>
<tr>
<td>Becker et al</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>5</td>
</tr>
<tr>
<td>Becker et al</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>5</td>
</tr>
<tr>
<td>Saaristo et al</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>5</td>
</tr>
<tr>
<td>Baumeister</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>4</td>
</tr>
<tr>
<td>Weiss et al</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>4</td>
</tr>
<tr>
<td>Furukawa et al</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>4</td>
</tr>
<tr>
<td>Chang et al</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>4</td>
</tr>
<tr>
<td>Damstra et al</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>4</td>
</tr>
<tr>
<td>Yamamoto et al</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>3</td>
</tr>
</tbody>
</table>

Abbreviations: BCRL, breast cancer-related lymphedema; FU, follow-up.
Table 2: Summary of studies on (composite) tissue transfer for the treatment of BCRL

<table>
<thead>
<tr>
<th>Ref</th>
<th>Intervention</th>
<th>Postoperative conservative treatment</th>
<th>n</th>
<th>FU</th>
<th>BCRL classification and stage</th>
<th>Duration of BCRL</th>
<th>Results</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lin et al</td>
<td>Inguinal fat pad with nodes and vascular structures set in dorsal wrist</td>
<td>Not mentioned</td>
<td>13</td>
<td>56 months (6–96)</td>
<td>−</td>
<td>2.8 years (4–84 months)</td>
<td>C: 12/13 pts had reduction, mean of 51% (range 0–71%). L: in all flow improvement. S: 11/13 had decrease cellulitis incidence</td>
<td>Wound infection (n = 1), venous congestion (n = 1), no donor site morbidity</td>
</tr>
<tr>
<td>Becker et al</td>
<td>Inguinal fat pad with nodes and vascular structures set in axilla of affected limb</td>
<td>No CG, MLD discontinued after 3 months</td>
<td>6</td>
<td>21 months (13–38)</td>
<td>−</td>
<td>−</td>
<td>C/V: lymphedema resolved in 5/6 pts. S: All pts had reduction in pain scale.</td>
<td>No donor or recipient site morbidity</td>
</tr>
<tr>
<td>Becker et al</td>
<td>Inguinal fat pad with nodes and vascular structures set in axilla of affected limb and in a second procedure (n = 7) inguinal fat pad set in elbow</td>
<td>No CG, 62.5% stopped MLD after 12 months</td>
<td>24</td>
<td>100 months (60–132)</td>
<td>2-Stage classification: I (n = 6) early edema, &lt;2 infectious episodes, limb circum &lt;30% difference. II (n = 18) edema &gt;1 year, &gt;2 infectious episodes, limb circum difference 30–50%</td>
<td>≥1-year average of 5.6 years (n = 18) ≤&lt;1-year average of 5 months (n = 6)</td>
<td>C: 6 &gt;50% reduction, 6 &lt;30% reduction, 10 returned to normal, 2 unchanged. L: 5/16 flow improvement.</td>
<td>Lymphorrhea (n = 8)</td>
</tr>
<tr>
<td>Saaristo et al</td>
<td>Combination of DIEP/msTRAM and inguinal fat pad with nodes and vascular structures set in axilla of affected limb after wide local scar excision (axilla)</td>
<td>33% discontinued MLD and CG after 8–24 months</td>
<td>9</td>
<td>6 months</td>
<td>−</td>
<td>43 months (6–120)</td>
<td>C: 7/9 had a reduction L: 5/16 had flow improvement</td>
<td>No donor site morbidity</td>
</tr>
<tr>
<td>Baumeister</td>
<td>Lymph vessel harvested from thigh interposed at upper arm/supraclavicular region</td>
<td>CG for 6 months</td>
<td>127</td>
<td>31 months</td>
<td>−</td>
<td>−</td>
<td>V: 22% average reduction DVT (n = 1), donor site edema (n = 1)</td>
<td>22–31% flow improvement (p &lt;0.01)</td>
</tr>
<tr>
<td>Weiss et al</td>
<td>Lymph vessels harvested from thigh interposed at upper arm/supraclavicular region</td>
<td>CG for 6 months</td>
<td>12</td>
<td>96 months</td>
<td>−</td>
<td>−</td>
<td>V: Reduction ranging 22–31% L: 11/12 significant flow improvement (p &lt;0.01)</td>
<td>−</td>
</tr>
</tbody>
</table>

Abbreviations: BCRL, breast cancer–related lymphedema; C, results measured by arm circumference; CG, compression garments; DVT, deep venous thrombosis; L, results measured by lymphoscintigraphy; MLD, manual lymph drainage; S, results measured by symptom assessment; V, results measured by arm volume. Note: Time of follow-up and duration of breast cancer–related lymphedema presented as mean and range.
Discussion

In this review, we summarized the available literature on derivative microsurgical techniques for the treatment of BCRL. We were primarily interested in the efficacy of derivative microsurgery and (composite) tissue transfer on upper-limb lymphedema and chronic lymphedema is an important postoperative conservative therapy postoperatively. Data could only be acquired through a mix of pro- and retrospective case series, as randomized or comparative studies were not available. This resulted in level IV evidence. With respect to the methodological quality, the studies on composite tissue transfer and lymphatic function and the discontinuation of conservation therapy. Data could only be acquired through a mix of pro- and retrospective case series, as randomized or comparative studies were not available. This resulted in level IV evidence. With respect to the methodological quality, the studies on composite tissue transfer ranged from 33 to 100% 3 months to 2 years after surgery. As differentiating between early and late complications, one case of donor site edema was reported. Although only ad

Table 3 Summary of studies on derivative (super) microlymphatic surgery for the treatment of BCRL.

<table>
<thead>
<tr>
<th>Ref</th>
<th>Intervention</th>
<th>Postoperative conservative treatment</th>
<th>n</th>
<th>FU</th>
<th>BCRL classification and stage</th>
<th>Duration of BCRL</th>
<th>Results</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furukawa et al</td>
<td>MLVI</td>
<td>CT for first 6 months</td>
<td>9</td>
<td>17 months (5–22)</td>
<td>–</td>
<td>7.3 years (1–13)</td>
<td>C: 77.8% of pts had &gt;50% reduction</td>
<td>–</td>
</tr>
<tr>
<td>Chang et al</td>
<td>Lymphaticovenular bypass</td>
<td>CT and CG continued indefinitely</td>
<td>20</td>
<td>12 months</td>
<td>Campisi classification: stage II (n = 10) and III (n = 10)</td>
<td>4.8 years (1–17)</td>
<td>V: 65% had reduction, average 35%</td>
<td>S: 80% had long-term symptom improvement</td>
</tr>
<tr>
<td>Damstra et al</td>
<td>LVA according to Degni-Cordeiro procedure</td>
<td>CG continued indefinitely</td>
<td>10</td>
<td>12 months</td>
<td>Campisi classification: stage III (n = 10)</td>
<td>5.3 years (3–14)</td>
<td>V: average reduction of 2%</td>
<td>S: 50% had subjective relief of complaints after 6 months</td>
</tr>
<tr>
<td>Yamamoto et al</td>
<td>MLVI</td>
<td>CG continued indefinitely</td>
<td>18</td>
<td>24 months (12–72)</td>
<td>–</td>
<td>7.1 years (1–23)</td>
<td>C: distal arm average reduction 54% (range 0–100%), proximal arm average reduction 45% (range 7.1–76.5%)</td>
<td>S: &gt;100% had subjective improvement</td>
</tr>
</tbody>
</table>

Abbreviations: BCRL, breast cancer–related lymphedema; C, results measured by arm circumference; CG, compression garments; CT, compression therapy; L, results measured by lymphoscintigraphy; LVA, lymphaticovenous anastomoses; MLVI, microsurgical lymphaticovenous implantation; Pts, patients; S, results measured by symptom assessment; V, results measured by arm volume. Note: Time of follow-up and duration of breast cancer–related lymphedema presented as mean and range.
outcome-determining factor, the recording of these lymphedema stages when selecting study patients is essential. Second, the postsurgical outcome assessment should not only include limb volume or circumference measurements but should also be complemented with monitoring of lymphatic flow.

Unfortunately, it was not possible to pool the results of the different studies included in this review due to incomplete data documentation, but most importantly because of the large difference between the studies with respect to the criteria used for selecting patients for surgery. For example, only four studies stratified patients into lymphedema clinical stages before ensuing surgery, whereas the others did not take the pathophysiological nature of lymphedema into account, resulting in a heterogeneous patient population.

Primary Outcomes
All but one study\(^{39}\) noted consistent reduction of upper-limb volume or circumference reduction from surgical intervention through derivative lymphatic surgery,\(^{37,38,40}\) lymph node transplantation\(^{1,31-34}\) or lymphatic vessel transfer.\(^{35,36}\) Damstra et al, reporting on results after lymphatic venous anastomosis, measured a disappointing mean volume difference of 2% after 1 year. There are, however, two aspects in the methodology of this study that might have affected the outcome. First, a surgical procedure according to Degni-Cordeiro was applied. This is a rather outdated technique originating from the early 1980s,\(^{41}\) a period in which derivative lymphatic surgery had proven low bypass patency due to the intravascular pressure gradient. Second, the selection criteria for the group of patients that would undergo derivative lymphatic surgery have affected the outcome of this study. It is stated by the authors that complete limb volume reduction was achieved in nearly half of the patient population when circumferential suction-assisted lipectomy was performed after the initial lymphatico-venous anastomosis. This suggests a chronic lymphedema stage. The natural progression of lymphedema sees to the change of limb swelling composition, from an at first predominantly fluid-containing entity to the addition of fibrosis, fat, and protein. So, even if the static lymph fluid is relieved, swelling still remains in the form of excess fat and fibrosis.\(^{42,43}\) Furthermore, chronic lymphedema also suggests a prolonged hypertensive state within the lymphatic system. This phenomenon causes irreversible damage to the lymph vessels (i.e., degeneration of smooth muscle cells),\(^{44,45}\) rendering the lymph vessels incapable of lymph fluid propulsion. Therefore, failure is inevitable in the attempts of producing patent lymphatic venous bypasses.

Aside from limb volume or circumference reduction, surgery effectiveness can be determined by lymphatic function. Lymphoscintigraphy can visualize lymphatic flow, providing qualitative information on lymph transport in the affected limb. Only half the studies\(^{31,33,34,36,39}\) assessed in this review evaluated the effect of lymphatic microsurgery on the lymphatic function. This is a major methodological flaw, as the ultimate aim of every lymphatic surgery should be to repair the function of the damaged lymphatic system. Moreover, in derivative surgery it is important to monitor lymphatic-venular bypass patency. Until recently there were no means of doing so. The use of indocyanine green fluorescence lymphangiography appears promising in this respect.\(^{46,47}\)

The effect of surgery on symptom relief was not a main focus for many of the studies in this review. A specific decrease in neuropathic pain and in cellulitis rates was reported in two small populations after lymph node transplantation.\(^{31,32}\) As for the effect of derivative lymphatic surgery, a subjective relief of symptoms was noted in 50 to 100% of the patients in three studies.\(^{38-40}\)

The discontinuation of postoperative conservative therapy was realized, although in variable rates, 3 to 24 months after surgery in the three studies evaluating inguinal lymph node transfer to the axilla of the lymph edematous arm.\(^{32-34}\) As reported,\(^{31,33}\) the results were better when the duration of lymphedema was the shortest before lymph node transfer, suggesting that this surgery cannot only be used as an alternative treatment for conservative therapy-resistant BCRL, but also as a curative up-front approach for lymphedema.

Even though we were limited to level IV evidence, a preference can be given to the inguinal lymph node transfer based on the reviewed literature. Not only was this the only technique that made the discontinuation of postoperative conservative therapy possible, it was also the technique described in better methodological quality studies compared with that of the other techniques. Furthermore, because this surgical procedure can be combined with autologous breast reconstruction, it might be easier to incorporate it into current breast cancer management programs.

Conclusion
An overview is presented of the current evidence base for the effectiveness of lymphatic microsurgery for the treatment of BCRL. We have identified important methodological shortcomings of the available literature. Evidence acquired through comparative prospective studies with uniform patient selection is lacking. The consistent positive findings with regard to limb volume/circumference reduction, and limited to no complications reported after microlymphatic surgery are, however, reasons to further explore these techniques in methodologically superior studies, perhaps answering the question as to when is the most appropriate time in the disease process for lymphatic surgery. We believe that the true contribution of microlymphatic surgery for the treatment of BCRL will only be elucidated through protocolized treatment initiation by experienced microsurgeons. In our institution we are currently in the process of setting up a prospective study: an integrated care program in which breast cancer patients are prospectively screened for lymphedema and are structurally treated with conservative therapy followed by lymph node transplantation or derivative surgery in conservative treatment-resistant cases.

References
15 Campisi C, Boccardo F. Role of microsurgery in the management of lymphoedema. Int Angiol 1999;18:47–51
20 Rohrich RJ, Eaves FF III. So you want to be an evidence-based plastic surgeon? A lifelong journey. Plast Reconstr Surg 2011;127:467–472